Neue Substanzen bei soliden Tumoren

Schlüsselwörter

Antikörper - Tyrosinkinaseinhibitoren - Antiangiogenese

Key words

antibodies - tyrosine kinase inhibitors - antiangiogenesis

Literatur

• 1 Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin J F, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?.  Br J Cancer. 2006;  94 259-267
• 2 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
• 3 Demetri G D, von Mehren M, Blanke C D, Van den Abbeele A D, Eisenberg B, Roberts P J. et al . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347 472-480
• 4 Demetri G D, van Oosterom A T, Blackstein M. et al . Phase III, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST.  J Clin Oncol. 2005;  23 308
• 5 Eisen T, Bukowski R M, Staehler M, Szczylik C, Oudard S, Stadler W M, Schwartz B, Simantov R, Shan M, Escudier B. For The Sorafenib TARGETs Clinical Trial Group . Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. 2006 ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2006;  24 (Suppl) 4524
• 6 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 7 Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson L C, Tervahartiala P, Tuveson D. et al . Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  344 1052-1056
• 8 Kabbinavar F F, Schulz J, McCleod M, Patel T, Hamm J T, Hecht J R, Mass R, Perrou B, Nelson B, Novotny W F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 3697-3705
• 9 Motzer R J, Hutson T E, Tomczak P, Michaelson M D, Bukowski R M, Rixe O, Oudard S, Kim S T, Baum C M, Figlin R A. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). 2006 ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2006;  24 (Suppl) LBA3
• 10 Piccart-Gebhart M J, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C H, Steger G, Huang C S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter T M, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci M S, Gelber R D. Herceptin Adjuvant (HERA) Trial Study Team . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 1659-1672
• 11 Romond E H, Perez E A, Bryant J, Suman V J, Geyer C E, Davidson N E, Tan-Chiu E, Martino S, Paik S, Kaufman P A, Swain S M, Pisansky T M, Fehrenbacher L, Kutteh L A, Vogel V G, Visscher D W, Yothers G, Jenkins R B, Brown A M, Dakhil S R, Mamounas E P, Lingle W L, Klein P M, Ingle J N, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.  N Engl J Med. 2005;  353 1673-1684
• 12 Singer S, Rubin B P, Lux M L, Chen C J, Demetri G D, Fletcher C DM. et al . Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors.  J Clin Oncol. 2002;  20 3898-3905
• 13 Shepherd F A, Rodrigues Pereira J, Ciuleanu T, Tan E H, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. National Cancer Institute of Canada Clinical Trials Group . Erlotinib in previously treated non-small-cell lung cancer.  N Engl J Med. 2005;  353 123-132
• 14 Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med. 2001;  344 783-792